Combination therapies of standard 7 + 3 with FLT3 inhibitors, as Midostaurin, in patients with FLT3-mutated AML [35] or gemtuzumab ozogamicin (GO) in CD33-positive favorable or intermediate risk AML [36] represent a new standard of care. Here, CD33 is linked to acute myeloid leukemia.